TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Trial of Evonail® Solution for Prevention or Treatment of Onycholysis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with breast cancer receiving adjuvant/neoadjuvant docetaxel chemotherapy~Exclusion Criteria:~* Patients with breast cancer receiving palliative docetaxel chemotherapy~* Patients having onycholysis before docetaxel treatment

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Experimental arm (Type: EXPERIMENTAL): In experimental arm, each patient painted EVONAIL® solution on nails and periungual areas once a day till developing onycholysis grade 2 or more.
- Control arm (Type: OTHER): In control arm, each patient painted EVONAIL® solution on nails and periungual area twice a day after developing onycholysis grade 2.~This study design allowed cross-over. Therefore, this control arm would give EVONAIL® solution after developing onlycholysis grade 2 in spite of control arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with relapsing remitting Multiple Sclerosis~* Patients with Expanded Disability Status Scale (EDSS) score of 0-6.5.~Exclusion Criteria:~* Patients with MS other than relapsing remitting MS~* Patients with a history of chronic disease of the immune system other than MS, which requires systemic immunosuppressive treatment, or a known immunodeficiency syndrome.~* Patients who have been treated with:~  * systemic corticosteroids or immunoglobulins within 1 month prior to baseline;~ * immunosuppressive medications within 3 months prior to baseline;~ * monoclonal antibodies within 3 months prior to baseline;~ * cladribine, mitoxantrone or alemtuzumab at any time.~* Uncontrolled diabetes mellitus at screening~* Diagnosis of macular edema during Screening Phase~* Patients with active systemic bacterial, viral or fungal infections, or known to have AIDS, Hepatitis B, Hepatitis C infection or to have positive HIV antibody, Hepatitis B surface antigen or Hepatitis C antibody tests.~* Patients who have received total lymphoid irradiation or bone marrow transplantation.~* Patients with certain cardiovascular conditions and/or findings in the screening ECG~* Patients with certain liver conditions~* Pregnant confirmed by a positive pregnancy test t or nursing (lactating) women~* Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Fingolimod (Type: EXPERIMENTAL): Open-label fingolimod 0.5 mg, taken orally once daily for 4 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Compensatory Kinematic Movements in Various Directions After Stroke

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~The inclusion criteria used in the randomized controlled trials were as follows:~Stroke~* Subject consisted of the physician's confirmation of chronic hemiplegia~* onset ≥ 6 months~* Mini-mental state examination≥25~* Biceps ≤2, Triceps≤2~* Ability to Sit on a chair alone~* FMA upper extremity score ≥ 21 points, FMA upper extremity ≤ 66 points~Healthy~* Age of matching the stroke group~* Absence of neurological disease and orthopedic disease~Exclusion Criteria:~Stroke~* Biceps\>2, Triceps\>2~* Flaccid~* Neglect syndrome~* Have neurological disease and orthopedic disease~* Lack of coordination

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- chronic stroke (Type: None): The subject consisted of the physician's confirmation of chronic hemiplegia onset ≥ 6 months Mini-mental state examination≥25 Biceps ≤2, Triceps≤2 Ability to Sit on a chair alone FMA upper extremity score ≥ 21points, FMA upper extremity score ≤ 66 points The symptom is mild or moderate level (MAS≤2) and can sit alone. The subject reaches to target by affected arm in 3 directions(medial_45, forward_90 and lateral_135 degrees)
- Healthy (Type: None): Matching aged people, not having neurological system or orthopedic disease on Upper extremity.~The subject reaches to target by non-dominant arm in 3 directions(medial_45, forward_90 and lateral_135 degrees)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase III Trial to Assess the Safety and Efficacy of Plant Cell Expressed GCD in Patients With Gaucher Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females, 18 years or older~* Confirmed enzymatic diagnosis of Gaucher disease~* Splenomegaly defined as greater than eight times the expected volume (measured volume divided by estimated volume (0.2% of body weight)\] as determined by MRI volumetric analysis~* Female patients of child-bearing potential who agree to use a medically acceptable method of contraception~* Thrombocytopenia (defined as platelet counts below the lower limit of normal) and/or anemia (defined by hemoglobin level at least 1 g/dL below normal range according to sex and age).~* Patients who have not received ERT in the past or patients whoc have not received ERT in the past 12 months and have a negative anti-glucocerebrosidase antibody test.~* Patients who have not received substrate reduction therapy (SRT) in the past 12 months.~* Ability to provide a written informed consent.~Exclusion Criteria:~* Currently taking another experimental drug for any condition~* Pregnant or nursing~* Presence of HIV and/or, HBsAg and/or hepatitis C infections~* Presence of severe neurological signs and symptoms, defined as complete ocular paralysis, overt myoclonus or history of seizures, characteristic of neuronopathic Gaucher disease.~* Previous anaphylactoid reaction to Cerezyme® or Ceredase®.~* History of allergy to carrots.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- prGCD 30 Units/kg (Type: EXPERIMENTAL): None
- prGCD 60 Units/kg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The AOT (Acridine Orange and Taurolidine) Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* informed consent~* patient on home TPN with central line (Hickman or Porth-a-cath)~* suspected central line infection (acridine orange test)~* proven central line infection (randomisation tauroline vs heparin)~Exclusion Criteria:~* no informed consent~* patient on home TPN with arteriovenous fistula (shunt)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Olmesartan/HCTZ 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Essential Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a diagnosis of essential hypertension, either treatment-naive or including currently on anti-hypertensive medication (in Italy only treatment naive patients) in whom it is medically justifiable to withdraw treatment , and who are likely to meet the required BP inclusion criteria at randomisation:~  * Mean sitting dBP ≥ 100 mmHg and ≤ 120 mmHg.~ * Mean sitting sBP ≥ 160 mmHg and ≤ 200 mmHg.~Main Exclusion Criteria:~* Mean sitting sBP values \> 200 mmHg and/or dBP \> 120 mmHg.~* Pregnant or nursing women.~* Patients with serious disorders which may limit the ability to evaluate the efficacy or safety of the tested medication, including cerebrovascular, cardiovascular, renal, respiratory, hepatic, gastrointestinal, endocrine or metabolic, haematological, oncological, neurological, and psychiatric diseases. The same applies for immunocompromised and/or neutropenic patients.~* Patients with secondary hypertension of any aetiology such as renal disease, pheochromocytoma, or Cushing's syndrome.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OM 40 (Type: ACTIVE_COMPARATOR): Olmesartanmedoxomil (OM)40 mg tablets.
- OM/HCTZ 40/12.5 (Type: EXPERIMENTAL): Olmesartanmedoxomil (OM) /Hydrochlorothiazide (HCTZ)40/12.5 mg tablets.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nab-Paclitaxel in Combination With Carboplatin as First-line Therapy in Patients With NSCLC

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed diagnosis of locally advanced / metastatic, unresectable NSCLC~* According to SmPC~Exclusion Criteria:~* According to SmPC

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Procalcitonin Levels in Patients With Fever and a Central Line

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age and younger~* Fever and a central venous catheter~* Presentation to an Emergency Department~* Central line secondary to Hematologic/Oncologic, Renal or Gastrointestinal disease~Exclusion Criteria:~* Intravenous antibiotics in the 24 hours prior to presentation~* PICC line~* Parental refusal or inability to provide consent

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Fever and a central venous catheter (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study in Healthy Tubal Ligated Women to Evaluate Pharmacodynamics, Safety and Pharmacokinetics of BAY1002670

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy female subjects~* Sterilized by tubal ligation~* Age 18-45 years~* Body mass index (BMI) at screening: ≥ 18 and ≤ 32 kg/m²~* At least 3 consecutive regular menstrual cycles with a cycle length of 24 - 35 days before first screening examination according to the subject's history~* Absence of clinically relevant abnormal findings in the pre-treatment endometrial biopsy~Exclusion Criteria:~* Regular use of medicines (incl. anabolics)~* Incompletely cured pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination and effects of the study drugs will not be normal~* Amenorrhea for more than 3 months within the last 6 months before the first screening examination~* Lacking suitability for frequent transvaginal ultrasonography (TVU) examinations~* Clinically relevant findings (e.g. blood pressure, electrocardiogram \[ECG\], physical and gynecological examination, laboratory examination)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- BAY1002670 [0.1mg] (Type: EXPERIMENTAL): 0.1 mg BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days
- BAY1002670 [0.5mg] (Type: EXPERIMENTAL): 0.5 mg BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days
- BAY1002670 [1.0mg] (Type: EXPERIMENTAL): 1.0 mg BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days
- BAY1002670 [2.0mg] (Type: EXPERIMENTAL): 2.0 mg BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days
- BAY1002670 [5.0mg] (Type: EXPERIMENTAL): 5.0 mg BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days
- Placebo (Type: PLACEBO_COMPARATOR): Placebo for BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase III Clinical Study to Evaluate the Efficacy and Safety of the Combination of Lercanidipine/Valsartan in Hypertensive Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged ≥ 20 to ≤75 years old~* Patient with essential hypertension~Exclusion Criteria:~* When the BP level measured at screening was sitDBP\>120 mmHg or sitSBP \>180 mmHg~* Patient with difference in repeatedly measured blood pressures from the selected arm at screening was sitSBP≥ 20mmHg or sitDBP ≥ 10mmHg

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Lercanidipine 10mg (Type: ACTIVE_COMPARATOR): 1 Tablet of Zanidip ® 10mg + 1 Tablet of L10/V80 Placebo + 1 Tablet of L10/V160 Placebo (8wks)
- Lercanidipine10mg /Valsartan 80mg (Type: EXPERIMENTAL): 1 Tablet of Zanidip ® 10mg Placebo +1 Tablet of L10/V80 + 1 Tablet of L10/V160 Placebo (8wks)
- Lercanidipine 10mg /Valsartan 160mg (Type: EXPERIMENTAL): 1 Tablet of Zanidip ® 10mg Placebo + 1 Tablet of L10/V80 Placebo + 1 Tablet of L10/ V160 (8wks)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Anticaries Effect of Xylitol,Probiotic and Chlorhexidine Mouth Rinses Among Individuals at High Risk

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Children aged 5-12 yrs at high risk for caries.~2. Elderly citizens (above 60 yrs) at high risk for caries.~3. Those willing to participate in the study and consented.~4. Not under antimicrobial therapy or used probiotic products during past 1 month.~Exclusion Criteria:~1. Using mouth rinse routinely.~2. Undergoing any dental treatment during the study period.~3. Not able to brush their teeth and rinse on their own.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Child Participants (Type: EXPERIMENTAL): Residential school children aged 5-12 yrs at high risk for caries. A total of 36 children will be recruited for the study and randomly divided into 3 groups with 12 participants per group.The subjects will be asked to rinse their mouth once daily (at night) for 2 minutes, using 15 ml of mouth rinse provided to them. The intervention will be carried out for a period of 14 days.
- Elderly Participants (Type: EXPERIMENTAL): Elderly citizens (above 60 yrs) at high risk for caries. A total of 36 elderly will be chosen based on eligibility criteria and randomly divided into 3 groups with 12 participants per group. The subjects will be asked to rinse their mouth once daily (at night) for 2 minutes, using 15 ml of mouth rinse provided to them. The intervention will be carried out for a period of 14 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Insulin Detemir and Insulin Aspart in 2 Separate Injections Twice Daily to Extemporaneous Mixing Injection Regimen Twice Daily - The Paediatric Mixing Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Parents' Informed Consent (IC) obtained before any trial-related activities~* Obtained child's assent (when possible)~* Type 1 diabetes~* Treatment with insulin detemir and insulin aspart either in extemporaneous mixed or separate injections~* HbA1c (glycosylated haemoglobin A1c) lesser than or equal to 8.6%~Exclusion Criteria:~* History of alcoholism, drug abuse, or psychiatric disease or personality disorders likely to invalidate voluntary consent or to prevent good compliance with the trial protocol~* Mental incapacity, unwillingness or language barrier precluding adequate understanding or co-operation~* Anticipated change or new use in concomitant medication known to interfere with glucose metabolism, such as systemic corticotherapy more than 5 mg/day (prednisone)~* Any other condition that the Investigator (trial physician) feels would interfere with trial participation or evaluation of results

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Mixed injection (Type: EXPERIMENTAL): None
- Separate injection (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria~* Patients scheduled for either elective unilateral or same-day bilateral total knee replacement surgery (TKR) or a revision of at least 1 component of a TKR~* Patients willing and able to undergo bilateral ascending contrast venography~Key Exclusion Criteria~* Known or suspected hereditary or acquired bleeding or coagulation disorders in the participant or his or her first-degree relative~* Known or suspected history of heparin-induced thrombocytopenia~* Known coagulopathy~* Active bleeding or at high risk for bleeding~* Brain, spinal, ophthalmologic, or major surgery or trauma within the past 90 days~* Active hepatobiliary disease~* Alcohol and/or substance abuse within the past year~* Any condition for which, in the opinion of the investigator, surgery or administration of an anticoagulant was contraindicated~* Two consecutive blood pressure readings within 15 to 30 minutes with supine systolic blood pressure \>180 mm Hg or supine diastolic blood pressure \>105 mm Hg~* Clinically significant laboratory abnormalities at the enrollment visit:~  * Hemoglobin \<10 g/dL~ * Platelet count \<100,000/mm\^3~ * Creatinine clearance \<30 mL/min, as estimated by the method of Cockcroft and Gault~ * Alanine aminotransferase or aspartate aminotransferase level \>2\*upper limit of normal (ULN) or a total bilirubin ≥1.5\*ULN (unless an alternative causative factor such as Gilbert's syndrome was identified)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Apixaban, 2.5 mg BID + Placebo (Type: EXPERIMENTAL): Participants received apixaban, 2.5-mg tablets twice daily (BID), plus a matching enoxaparin-placebo injection 12 (±3) hours prior to hip-replacement surgery through 11 (±2) days after the day of surgery.
- Enoxaparin, 40 mg QD + Placebo (Type: ACTIVE_COMPARATOR): Participants received enoxaparin, 40-mg subcutaneous injection once daily (QD), plus a matching apixaban-placebo tablet 12 (±3) hours prior to hip-replacement surgery through 11 (±2) days after the day of surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete